Scribe Therapeutics Inc. (NASDAQ:SCTX) Short Interest Up ∞ in July

Posted by Francis Steltz on Aug 18th, 2026

Scribe Therapeutics Inc. (NASDAQ:SCTX – Get Free Report) was the recipient of a large growth in short interest in the month of July. As of July 31st, there was short interest totaling 263,070 shares, a growth of ∞ from the July 15th total of 0 shares. Approximately 1.5% of the shares of the company are sold short. Based on an average trading volume of 195,886 shares, the short-interest ratio is currently 1.3 days.

Scribe Therapeutics Stock Performance

Shares of SCTX opened at $21.19 on Tuesday. Scribe Therapeutics has a twelve month low of $17.31 and a twelve month high of $26.50.

Insider Buying and Selling

In related news, Director Carl L. Gordon bought 1,000,000 shares of the stock in a transaction on Monday, July 27th. The shares were bought at an average cost of $15.00 per share, for a total transaction of $15,000,000.00. Following the purchase, the director owned 1,348,825 shares of the company’s stock, valued at $20,232,375. This trade represents a 286.68% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO David Parrot bought 2,666 shares of the company’s stock in a transaction dated Thursday, July 23rd. The stock was bought at an average cost of $15.00 per share, for a total transaction of $39,990.00. Following the acquisition, the chief financial officer owned 1,333 shares of the company’s stock, valued at approximately $19,995. This trade represents a -200.00% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought 3,727,237 shares of company stock valued at $56,291,746 in the last quarter.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen upgraded shares of Scribe Therapeutics to a “hold” rating in a research report on Saturday, August 1st.

Get Our Latest Report on Scribe Therapeutics

About Scribe Therapeutics

(Get Free Report)

Scribe Therapeutics Inc is a clinical-stage biotechnology company engineering CRISPR-based technologies into purpose-built in vivo genetic medicines designed to become standard of care treatments for patients suffering from highly prevalent diseases, starting with cardiometabolic disease. Scribe Therapeutics Inc is based in ALAMEDA, Calif.